Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539246 | 0.81 | PARP10 (0.48) | AKR1C3AKR1C2PDE2ATSHRCA1 | |
| SCHEMBL16161046 | 0.78 | AKR1C3 (0.41) | AKR1C3AKR1C2PTGS1PDE2AHDAC6 | |
| SCHEMBL1194001 | 0.78 | TSHR (0.60) | AKR1C3AKR1C2PTGS1CES2CES1 | |
| SCHEMBL8737307 | 0.76 | MAPT (0.48) | AKR1C3AKR1C2PDE2A | |
| SCHEMBL8045036 | 0.76 | ALDH1A1 (0.43) | AKR1C3AKR1C2PTGS1PDE2AHDAC6 | |
| SCHEMBL20560502 | 0.74 | AKR1C3 (0.39) | AKR1C3AKR1C2PTGS1PDE2AHDAC6 | |
| SCHEMBL21585246 | 0.73 | ALDH1A1 (0.61) | AKR1C3AKR1C2PTGS1CES2CES1 | |
| SCHEMBL1970199 | 0.72 | PDE2A (0.52) | AKR1C3AKR1C2PTGS1PDE2AKDM1A | |
| SCHEMBL1259812 | 0.72 | CES2 (0.62) | CES2CES1CA1CA2 | |
| SCHEMBL16110122 | 0.71 | PTPN1 (0.61) | AKR1C3AKR1C2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079878-B2 | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators | PFIZER LIMITED (GB) | 2015-07-14 | — | — | US | disclosed |
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | PFIZER LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | SCN8A, SCN1A, SCN5A | AKR1C3 2043/4885AKR1C2 2593/4885PTGS1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.